Follow
Roger Bruggemann
Roger Bruggemann
Unknown affiliation
Verified email at radboudumc.nl
Title
Cited by
Cited by
Year
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, ...
Clinical Microbiology and Infection 24, e1-e38, 2018
12652018
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ...
The Lancet Infectious Diseases 21 (6), e149-e162, 2021
7332021
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents
RJM Brüggemann, JWC Alffenaar, NMA Blijlevens, EM Billaud, ...
Clinical Infectious Diseases 48 (10), 1441-1458, 2009
4792009
Tackling the emerging threat of antifungal resistance to human health
MC Fisher, A Alastruey-Izquierdo, J Berman, T Bicanic, EM Bignell, ...
Nature reviews microbiology 20 (9), 557-571, 2022
3962022
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
PE Verweij, BJA Rijnders, RJM Brüggemann, E Azoulay, M Bassetti, ...
Intensive care medicine 46 (8), 1524-1535, 2020
3272020
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
PE Verweij, M Ananda-Rajah, D Andes, MC Arendrup, RJ Brüggemann, ...
Drug Resistance Updates 21, 30-40, 2015
3212015
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
FL van de Veerdonk, MG Netea, M van Deuren, JWM van der Meer, ...
Elife 9, e57555, 2020
3152020
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
JA Maertens, C Girmenia, RJ Brüggemann, RF Duarte, CC Kibbler, ...
Journal of Antimicrobial Chemotherapy 73 (12), 3221-3230, 2018
2822018
Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial
M Van Den Boogaard, AJC Slooter, RJM Brüggemann, L Schoonhoven, ...
Jama 319 (7), 680-690, 2018
2682018
Antifungal drugs: what brings the future?
R Van Daele, I Spriet, J Wauters, J Maertens, T Mercier, S Van Hecke, ...
Medical mycology 57 (Supplement_3), S328-S343, 2019
2032019
Diagnosing COVID-19-associated pulmonary aspergillosis
PE Verweij, JP Gangneux, M Bassetti, RJM Brüggemann, OA Cornely, ...
The Lancet Microbe 1 (2), e53-e55, 2020
1912020
Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters
C Smit, S De Hoogd, RJM Brüggemann, CAJ Knibbe
Expert opinion on drug metabolism & toxicology 14 (3), 275-285, 2018
1862018
Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis
L Wong, Z Radić, RJM Brüggemann, N Hosea, HA Berman, P Taylor
Biochemistry 39 (19), 5750-5757, 2000
1662000
Therapeutic drug monitoring of voriconazole
RJM Brüggemann, JP Donnelly, RE Aarnoutse, A Warris, NMA Blijlevens, ...
Therapeutic drug monitoring 30 (4), 403-411, 2008
164*2008
Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines
M Mikulska, D Averbuch, F Tissot, C Cordonnier, M Akova, T Calandra, ...
Journal of Infection 76 (1), 20-37, 2018
1612018
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
A Warris, T Lehrnbecher, E Roilides, E Castagnola, RJM Brüggemann, ...
Clinical Microbiology and Infection 25 (9), 1096-1113, 2019
1522019
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
E Mavridou, RJM Brüggemann, WJG Melchers, JW Mouton, PE Verweij
Antimicrobial agents and chemotherapy 54 (2), 860-865, 2010
1342010
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis
PE Verweij, RJM Brüggemann, E Azoulay, M Bassetti, S Blot, JB Buil, ...
Intensive care medicine 47 (8), 819-834, 2021
1262021
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections
T Tängdén, V Ramos Martín, TW Felton, EI Nielsen, S Marchand, ...
Intensive care medicine 43, 1021-1032, 2017
1252017
Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4
AH Groll, R Townsend, A Desai, N Azie, M Jones, M Engelhardt, ...
Transplant Infectious Disease 19 (5), e12751, 2017
1152017
The system can't perform the operation now. Try again later.
Articles 1–20